Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Kimberly S. Corbin*, William G. Breen, Jonathan B. Strauss

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.

Original languageEnglish (US)
Pages (from-to)99-101
Number of pages3
JournalClinical and Translational Radiation Oncology
Volume24
DOIs
StatePublished - Sep 2020

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)'. Together they form a unique fingerprint.

Cite this